Internationally-renowned geneticist and neurobiologist with decades of hearing research leadership to head Sensorion’s Scientific Advisory Board
MONTPELLIER, France, May 22, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that Professor Christine Petit, M.D., Ph.D. will be appointed as the Chair of its Scientific Advisory Board.
Professor Christine Petit presently serves concurrently as Professor at College de France, Chair of Genetics and Cellular Physiology, Professor at Institut Pasteur (Paris) and Head of the Laboratory of Genetics and Physiology of Hearing of the Pasteur Institute, affiliated to INSERM (UMRS 1120) and Sorbonne University (Paris).
Among her most notable accomplishments are deciphering the genetic basis for human deafness, elucidating key molecular machineries for sound reception and encoding, and uncovering pathogenic processes for a large variety of hearing deficits. Based on these findings, she is now developing curative therapies for deafness. She has been the recipient of numerous prestigious awards for her scientific contributions, such as the ARO Lifetime Achievement Award of Merit (USA), the International Brain Prize from Grete Lundbeck Foundation, The Hughes Knowles Prize (USA), the Louis-Jeantet for Medicine Prize for her outstanding contribution to the understanding of the auditory science (Europe), the l’Oréal-Unesco Award recognizing outstanding Women in Sciences (Europe) and the Grand Prize from the INSERM (France).
She is a member of the French and American Sciences Academies and the American Medical Academy.
“Professor Christine Petit has a profound and multidisciplinary understanding of hearing and has made paradigm-changing discoveries in the field,” said Nawal Ouzren, Chief Executive Officer of Sensorion. “We are humbled and honored to have an established leader and world-renowned scientist of Professor Petit’s caliber joining Sensorion. We are confident that her guidance, expertise and experience will serve as invaluable assets to our company and to our efforts in providing better treatment options for those suffering from inner ear diseases.”
Professor Christine Petit will lead the French Hearing Institute coupled to an innovative research center in human audiology, which will open early 2019 in Paris. It aims to advance knowledge in auditory neurosciences and to develop new diagnostic and therapeutic approaches.
About Sensorion Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: SENS-111, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.
Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.
Contacts
| Sensorion Nawal Ouzren CEO contact@sensorion-pharma.com Tél : +33(0) 467 207 730 | Investor Relations LifeSci Advisors LLC Chris Maggos chris@lifesciadvisors.com Tél. : +41 79 367 6254 |
| Label : SENSORION | Press |
| ISIN : FR0012596468 | Alize RP |
| Mnemonic : ALSEN | Caroline Carmagnol & Wendy Rigal |
| sensorion@alizerp.com |
Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
